Bevasiranib trial for wet-AMD discontinued
OPKO Health announced that it is terminating a phase 3 trial of bevasiranib for the treatment of wet age-related macular degeneration (wet-AMD).
OPKO Health announced that it is terminating a phase 3 trial of bevasiranib for the treatment of wet age-related macular degeneration (wet-AMD).
An analysis of the preliminary data conducted by an independent data monitoring committee demonstrated that the trial was unlikely to meet its primary end point (improvement in visual acuity), although bevasiranib used adjunctively with ranibizumab (Lucentis, Genentech) did show activity in this disease state.
No systemic safety issues were identified in the trial.
Employers Face Barriers With Adopting Biosimilars
March 1st 2022Despite the promise of savings billions of dollars in the United States, adoption of biosimilars has been slow. A roundtable discussion among employers highlighted some of the barriers, including formulary design and drug pricing and rebates.
